Markers of coagulation activation, such as cross-linked fibrin degradation products (D-dimer), prothrombin fragment 1+2 (PF1+2), Thombin-antithrombin complex (TAT), von Willebrand factor (vWF), circulating procoagulant MPs, and the manifestation of thrombosic events are associated with tumor progression and prognosis (71–73). The gene discussed is PHF12; the disease is neoplasm.